{"id":817457,"date":"2025-02-25T08:08:22","date_gmt":"2025-02-25T13:08:22","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-to-participate-at-upcoming-investor-conferences-in-march\/"},"modified":"2025-02-25T08:08:22","modified_gmt":"2025-02-25T13:08:22","slug":"newamsterdam-pharma-to-participate-at-upcoming-investor-conferences-in-march","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-to-participate-at-upcoming-investor-conferences-in-march\/","title":{"rendered":"NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">NAARDEN, The Netherlands and MIAMI, Feb.  25, 2025  (GLOBE NEWSWIRE) &#8212; NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or \u201cNewAmsterdam\u201d or the \u201cCompany\u201d), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (\u201cCVD\u201d) with elevated low-density lipoprotein cholesterol (\u201cLDL-C\u201d), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that company management will participate in the following upcoming investor conferences:<\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:8pt\">\n          <strong>TD Cowen 45<\/strong><br \/>\n          <sup><br \/>\n            <strong>th<\/strong><br \/>\n          <\/sup><br \/>\n          <strong> Annual Healthcare Conference<\/strong> in Boston, MA on Tuesday, March 4 and Wednesday, March 5, 2025. Michael Davidson, M.D., Chief Executive Officer, and Ian Somaiya, Chief Financial Officer, will present a corporate overview at 1:50 p.m. ET on Tuesday, March 4.<\/li>\n<li style=\"margin-bottom:2pt\">\n          <strong>Leerink Partners Global Healthcare Conference 2025<\/strong> in Miami, FL on Monday, March 10, 2025. Michael Davidson, M.D., Chief Executive Officer, will present a corporate overview at 8:00 a.m. ET.<\/li>\n<li style=\"margin-bottom:2pt\">\n          <strong>Jefferies Biotech on the Beach Summit<\/strong> in Miami, FL on Wednesday, March 12, 2025. Company management will be available for 1&#215;1 meetings throughout the day.<\/li>\n<\/ul>\n<p>Live webcasts of both presentations will be available through the investor relations section of the NewAmsterdam Pharma website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=WG6eX_bZ4Cvh6XfyQHmhn0EUTdBChxngXi6D_dq-CHgS20h52vCeGbRu1Tsagsk7Xv2JKn8dTYle_3v-EoehPtAWGYexYzdnnsH6mPoH5Jv7xpEcb323F_RD-_jASvh2\" rel=\"nofollow\" target=\"_blank\">ir.newamsterdampharma.com<\/a>. Following the live webcast, an archived replay will be available on the Company\u2019s website.<\/p>\n<p>\n        <strong>About NewAmsterdam<\/strong>\n      <\/p>\n<p>NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage, clinical biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple Phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.<\/p>\n<p>\n        <strong>Company Contact<br \/><\/strong>Matthew Philippe<br \/>P: 1-917-882-7512<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GlRk2y7UJEpoxnMGrryUhKiyvUS2FvCDzop06JqjxjQRoZi_o9iveda-8s840Mg1Bs-FKTeXJYqW3jUdEE4mrMWW4Wall4aJgLMkUAtAQiFIuhkwA9789HYA5tWaBeeo1O5HGzRX8pnYyt_UM0_i2Q==\" rel=\"nofollow\" target=\"_blank\">matthew.philippe@newamsterdampharma.com<\/a><\/p>\n<p>\n        <strong>Media Contact<br \/><\/strong>Spectrum Science on behalf of NewAmsterdam<br \/>Jaryd Leady<br \/>P: 1-856-803-7855<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6eDxe30gLPVrn1XjQYZ_WoT_aMGlBFXilzbxJa_1afi6hTsF8W3rt4OdZQr42bbRKBW8wEOIdMWNiaWrViE9WPh3Y-42T_bIE2_jIY1ojn_xnbZbJOXfCrHE64fMItem\" rel=\"nofollow\" target=\"_blank\">jleady@spectrumscience.com<\/a><\/p>\n<p>\n        <strong>Investor Contact<br \/><\/strong>Precision AQ on behalf of NewAmsterdam<br \/>Austin Murtagh<br \/>P: 1-212-698-8696<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=LjPtjC1bigPy_sJgkvAPYb4iZP0i0fu3G7HAa6Cf2hMpG2X3U-dYkclwxt3FgLrNIVlMBAGR6K_DoZQy-4TslvShseR5qlcc-sftEbrC95XZqBzRKO0p1wCksblRhTze\" rel=\"nofollow\" target=\"_blank\">austin.murtagh@precisionaq.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4MzQwNiM2Nzc1MDg0IzIyNTAzNDE=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MjQyOTY2NmMtMjA0Ny00ODRiLWJiNDEtMDFmOTkwYWQ4Y2VlLTEyNjE4OTQ=\/tiny\/NewAmsterdam-Pharma-N-V-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NAARDEN, The Netherlands and MIAMI, Feb. 25, 2025 (GLOBE NEWSWIRE) &#8212; NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or \u201cNewAmsterdam\u201d or the \u201cCompany\u201d), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (\u201cCVD\u201d) with elevated low-density lipoprotein cholesterol (\u201cLDL-C\u201d), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that company management will participate in the following upcoming investor conferences: TD Cowen 45 th Annual Healthcare Conference in Boston, MA on Tuesday, March 4 and Wednesday, March 5, 2025. Michael Davidson, M.D., Chief Executive Officer, and Ian Somaiya, Chief Financial Officer, will present a corporate overview at 1:50 p.m. ET on Tuesday, March 4. Leerink Partners Global Healthcare Conference 2025 in Miami, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-to-participate-at-upcoming-investor-conferences-in-march\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-817457","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-to-participate-at-upcoming-investor-conferences-in-march\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NAARDEN, The Netherlands and MIAMI, Feb. 25, 2025 (GLOBE NEWSWIRE) &#8212; NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or \u201cNewAmsterdam\u201d or the \u201cCompany\u201d), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (\u201cCVD\u201d) with elevated low-density lipoprotein cholesterol (\u201cLDL-C\u201d), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that company management will participate in the following upcoming investor conferences: TD Cowen 45 th Annual Healthcare Conference in Boston, MA on Tuesday, March 4 and Wednesday, March 5, 2025. Michael Davidson, M.D., Chief Executive Officer, and Ian Somaiya, Chief Financial Officer, will present a corporate overview at 1:50 p.m. ET on Tuesday, March 4. Leerink Partners Global Healthcare Conference 2025 in Miami, &hellip; Continue reading &quot;NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-to-participate-at-upcoming-investor-conferences-in-march\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-25T13:08:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4MzQwNiM2Nzc1MDg0IzIyNTAzNDE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/newamsterdam-pharma-to-participate-at-upcoming-investor-conferences-in-march\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/newamsterdam-pharma-to-participate-at-upcoming-investor-conferences-in-march\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March\",\"datePublished\":\"2025-02-25T13:08:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/newamsterdam-pharma-to-participate-at-upcoming-investor-conferences-in-march\\\/\"},\"wordCount\":353,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/newamsterdam-pharma-to-participate-at-upcoming-investor-conferences-in-march\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4MzQwNiM2Nzc1MDg0IzIyNTAzNDE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/newamsterdam-pharma-to-participate-at-upcoming-investor-conferences-in-march\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/newamsterdam-pharma-to-participate-at-upcoming-investor-conferences-in-march\\\/\",\"name\":\"NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/newamsterdam-pharma-to-participate-at-upcoming-investor-conferences-in-march\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/newamsterdam-pharma-to-participate-at-upcoming-investor-conferences-in-march\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4MzQwNiM2Nzc1MDg0IzIyNTAzNDE=\",\"datePublished\":\"2025-02-25T13:08:22+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/newamsterdam-pharma-to-participate-at-upcoming-investor-conferences-in-march\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/newamsterdam-pharma-to-participate-at-upcoming-investor-conferences-in-march\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/newamsterdam-pharma-to-participate-at-upcoming-investor-conferences-in-march\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4MzQwNiM2Nzc1MDg0IzIyNTAzNDE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4MzQwNiM2Nzc1MDg0IzIyNTAzNDE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/newamsterdam-pharma-to-participate-at-upcoming-investor-conferences-in-march\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-to-participate-at-upcoming-investor-conferences-in-march\/","og_locale":"en_US","og_type":"article","og_title":"NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March - Market Newsdesk","og_description":"NAARDEN, The Netherlands and MIAMI, Feb. 25, 2025 (GLOBE NEWSWIRE) &#8212; NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or \u201cNewAmsterdam\u201d or the \u201cCompany\u201d), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (\u201cCVD\u201d) with elevated low-density lipoprotein cholesterol (\u201cLDL-C\u201d), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that company management will participate in the following upcoming investor conferences: TD Cowen 45 th Annual Healthcare Conference in Boston, MA on Tuesday, March 4 and Wednesday, March 5, 2025. Michael Davidson, M.D., Chief Executive Officer, and Ian Somaiya, Chief Financial Officer, will present a corporate overview at 1:50 p.m. ET on Tuesday, March 4. Leerink Partners Global Healthcare Conference 2025 in Miami, &hellip; Continue reading \"NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-to-participate-at-upcoming-investor-conferences-in-march\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-25T13:08:22+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4MzQwNiM2Nzc1MDg0IzIyNTAzNDE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-to-participate-at-upcoming-investor-conferences-in-march\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-to-participate-at-upcoming-investor-conferences-in-march\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March","datePublished":"2025-02-25T13:08:22+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-to-participate-at-upcoming-investor-conferences-in-march\/"},"wordCount":353,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-to-participate-at-upcoming-investor-conferences-in-march\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4MzQwNiM2Nzc1MDg0IzIyNTAzNDE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-to-participate-at-upcoming-investor-conferences-in-march\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-to-participate-at-upcoming-investor-conferences-in-march\/","name":"NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-to-participate-at-upcoming-investor-conferences-in-march\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-to-participate-at-upcoming-investor-conferences-in-march\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4MzQwNiM2Nzc1MDg0IzIyNTAzNDE=","datePublished":"2025-02-25T13:08:22+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-to-participate-at-upcoming-investor-conferences-in-march\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-to-participate-at-upcoming-investor-conferences-in-march\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-to-participate-at-upcoming-investor-conferences-in-march\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4MzQwNiM2Nzc1MDg0IzIyNTAzNDE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4MzQwNiM2Nzc1MDg0IzIyNTAzNDE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-to-participate-at-upcoming-investor-conferences-in-march\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/817457","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=817457"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/817457\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=817457"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=817457"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=817457"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}